Quantcast

Latest Genomic Health Inc. Stories

2014-09-29 08:31:04

Strongly Positive Results, Presented at European Society for Medical Oncology (ESMO) 2014 Congress, Demonstrated Oncotype DX® Prostate Cancer Test was an Independent Predictor of Tumor Aggressiveness REDWOOD CITY, Calif., Sept. 29, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University...

2014-09-26 08:25:45

Results from First Clinical Study Using NGS-based Proprietary Liquid Biopsy Platform to Detect Presence of Breast Cancer Also Will Be Presented REDWOOD CITY, Calif., Sept. 26, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from a second large, independent clinical validation study of Oncotype DX® in patients with a pre-invasive form of breast cancer known as DCIS (ductal carcinoma in situ) will be featured as an oral presentation at the 37(th) Annual...

2014-09-24 08:27:58

Prostate Cancer Survivor Joe Torre, Three Prominent Advocacy Organizations and Genomic Health Partner to Encourage Men to Seek Genomic Testing to Enable More Confident Treatment Decisions and Avoid Life-altering Side Effects REDWOOD CITY, Calif., Sept. 24, 2014 /PRNewswire/ -- In partnership with Men's Health Network (MHN), Prostate Health Education Network (PHEN), ZERO - the End of Prostate Cancer and Joe Torre, four-time world champion baseball Hall-of-Famer and prostate cancer survivor,...

2014-09-12 08:23:43

Results Suggest that Oncotype DX® Colon Cancer Test May Reduce Medical Costs Associated with Stage II Disease While Increasing Patient Well-being REDWOOD CITY, Calif., Sept. 12, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that PharmacoEconomics published positive results from a health economic analysis suggesting that use of the Oncotype® DX colon cancer test may result in a significant reduction in direct medical costs and improve patient quality of...

2014-09-09 08:31:36

Additional Data Acceptances Include Multiple Oncotype DX® Studies in Breast and Renal Cancers REDWOOD CITY, Calif., Sept. 9, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX(®) in prostate, breast and renal cancers will be presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, September 26 - 30. Included in the program is the first presentation of strongly positive results from an...

2014-08-19 12:28:27

First Kit Improves RNA-Seq for FFPE and High-Quality RNA Samples IPSWICH, Mass., Aug. 19, 2014 /PRNewswire/ -- New England Biolabs, Inc. (NEB(®)) today announced that NEB has exclusively in-licensed rights from Genomic Health, Inc. to its technology for the depletion of abundant RNAs, which is instrumental to performing sensitive RNA-seq experiments at a lower cost. http://photos.prnewswire.com/prnvar/20090921/NE79207LOGO-b Ribosomal RNAs (rRNAs) are extremely abundant,...

2014-08-08 08:26:06

REDWOOD CITY, Calif., Aug. 8, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole, Chief Operating Officer and Chief Financial Officer, will present at the 34(th) Annual Canaccord Growth Conference in Boston on Wednesday, August 13 at 10:30 a.m. Eastern Time (ET). http://photos.prnewswire.com/prnvar/20130425/SF01493LOGO To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the...

2014-08-07 16:28:34

17% Increase in Test Volume, 11% Increase in Total Revenue and 29% Increase in International Product Revenue Compared to Prior Year REDWOOD CITY, Calif., Aug. 7, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June 30, 2014. Product revenue was $70.5 million in the second quarter of 2014, compared with $63.7 million for the second quarter of 2013, an increase of 11 percent. There was no contract revenue in...

2014-08-06 08:31:58

Study Achieved Primary Endpoint of Predicting Recurrence after Surgery and Reconfirmed Original Adverse Pathology Endpoint from Published UCSF Validation Study REDWOOD CITY, Calif., Aug. 6, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX(®) Genomic Prostate Score (GPS) predicts...

2014-07-31 08:35:54

REDWOOD CITY, Calif., July 31, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Thursday, August 7 at 4:30 p.m. Eastern Time to discuss its second quarter 2014 financial results. The call and webcast will follow the release of the second quarter financial results after market close. http://photos.prnewswire.com/prnvar/20130425/SF01493LOGO Conference Call DetailsTo access the live conference call on...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin